Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Arsela Prelaj, Rebecca Yin Tay, Roberto Ferrara et al. · European Journal of Cancer · 2018
Cited by 193 works. doi:10.1016/j.ejca.2018.11.002
Authors
References
- Hallmarks of Cancer: The Next Generation
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade